利奈唑胺联合美罗培南对重症肺炎患者血清炎性因子及肺功能的影响

Effect of linezolid combined with meropenem on serum inflammatory factors and pulmonary function in patients with severe pneumonia

目的探讨利奈唑胺联合美罗培南对重症肺炎患者血清炎性因子及肺功能的影响。方法抽取威海市中心医院2019年1月至2022年1月收治的110例重症肺炎患者,按随机数字表法分为对照组与观察组,每组55例。对照组予以美罗培南治疗,观察组加用利奈唑胺治疗,均持续治疗2周。比较两组临床疗效、血清炎性因子水平、肺功能及安全性。结果观察组治疗总有效率(92.37%,51/55)高于对照组(76.36%,42/55),P<0.05。治疗前,两组血清炎性因子、肺功能比较差异未见统计学意义(P>0.05);治疗后,观察组肿瘤坏死因子-α、白细胞介素-6、降钙素原、高敏C反应蛋白水平均低于对照组(P均<0.05),最大呼气中段流量、最大呼气压、用力呼气量占用力肺活量比值、最大吸气压、呼气峰流速水平均高于对照组(P均<0.05)。两组不良反应发生率比较差异未见统计学意义(P>0.05)。结论利奈唑胺联合美罗培南能够有效降低重症肺炎患者血清炎性因子水平,改善肺功能,且安全可靠。

Objective To investigate the effects of linezolid combined with meropenem on serum inflammatory factors and pulmonary function in patients with severe pneumonia.Methods A total of 110 patients with severe pneumonia admitted to Weihai Central Hospital from January 2019 to January 2022 were selected,and they were divided into control group and observation group by random number table method,with 55 patients in each group.The control group was treated with meropenem,and the observation group was treated with linezolid based on the treatment of the control group,the two groups were all treated for 2 weeks continuously.The clinical efficacy,serum inflammatory factors,pulmonary function and safety of the two groups were compared.Results The total effective rate of the observation group(92.37%,51/55)was higher than that of the control group(76.36%,42/55),P<0.05.There was no significant difference in serum inflammatory factors and lung function between the two groups before treatment(P>0.05).After treatment,tumor necrosis factor-α,interleukin-6,procalcitonin and high-sensitivity C-reactive protein in the observation group were lower than those in the control group(all P<0.05).The levels of maximum expiratory middle flow,maximum expiratory pressure,ratio of forced expiratory volume to forced vital capacity,maximum inspiratory pressure and peak expiratory flow rate in the observation group were higher than those in the control group(all P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions Linezolid combined with meropenem can effectively reduce the level of serum inflammatory factors in patients with severe pneumonia,improve pulmonary function,and it is safe and reliable.